Keynote: State of Biopharma — Rethinking Innovation Amid a Shifting Landscape

The biopharma industry is heading into uncharted territory. With a wave of high-revenue biologics approaching patent expiry, companies are staring down a potential $300 billion cliff, one that could redraw the competitive map entirely. At the same time, R&D pipelines are thinning, once-promising therapeutic areas are showing signs of saturation, and oncology continues to dominate at the expense of broader diversification.

But it’s not all retreat; this inflection point is also giving rise to a new class of innovation. From AI-driven molecule discovery to synthetic biology platforms and cell-based manufacturing, the industry is quietly laying the groundwork for a transformation that could be as disruptive as it is overdue.